3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome and Myasthenia Gravis†

  1. DONALD B. SANDERS1,
  2. JAMES F. HOWARD JR2,
  3. JANICE M. MASSEY1

Article first published online: 17 DEC 2006

DOI: 10.1111/j.1749-6632.1993.tb22949.x

Issue

Annals of the New York Academy of Sciences

Annals of the New York Academy of Sciences

Additional Information

How to Cite

SANDERS, D. B., HOWARD, J. F. and MASSEY, J. M. (1993), 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome and Myasthenia Gravis. Annals of the New York Academy of Sciences, 681: 588–590. doi: 10.1111/j.1749-6632.1993.tb22949.x

Author Information

  1. 1

    Duke University Medical Center, Box 3403 Durham, North Carolina 27710

  2. 2

    University of North Carolina, Medical School at Chapel Hill Chapel Hill, North Carolina

  • †

    This work was supported by the GCRC Program Grant, NCRR, NIH, and USPHS Grant FD-U-000460.

Publication History

  1. Issue published online: 17 DEC 2006
  2. Article first published online: 17 DEC 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (150K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    D. M. Green, A. C. Jones, K. R. Brain, Content variability of active drug substance in compounded oral 3,4-diaminopyridine products, Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 1
    Direct Link:
  2. 2
    Tulio E Bertorini, Hani Rashed, Mitzi Zeno, Elizabeth A Tolley, Masanori Igarashi, Yingjun D Li, Effects of 3-4 Diaminopyridine (DAP) in Motor Neuron Diseases, Journal of Clinical Neuromuscular Disease, 2011, 12, 3, 129

    CrossRef

  3. 3
    Shin J. Oh, Neuromuscular Disorders: Treatment and Management, 2011,

    CrossRef

  4. 4
    Laurent Flet, Elisabeth Polard, Olivia Guillard, Emmanuelle Leray, Hervé Allain, Loïc Javaudin, Gilles Edan, 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study, Journal of Neurology, 2010, 257, 6, 937

    CrossRef

  5. 5
    A. Quartel, S. Turbeville, D. Lounsbury, Current therapy for Lambert–Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment, Current Medical Research and Opinion, 2010, 26, 6, 1363

    CrossRef

  6. 6
    Andrew G. Engel, The therapy of congenital myasthenic syndromes, Neurotherapeutics, 2007, 4, 2, 252

    CrossRef

  7. 7
    S Goulay-Dufaÿ, B Do, M.D Le Hoang, J.A Raust, H Graffard, F Guyon, D Pradeau, Determination of A 3,4-diaminopyridine in plasma by liquid chromatography with electrochemical detection using solid-phase extraction, Journal of Chromatography B, 2004, 805, 2, 261

    CrossRef

  8. 8
    DONALD B. SANDERS, Lambert-Eaton Myasthenic Syndrome, Annals of the New York Academy of Sciences, 2003, 998, 1
    Direct Link:
  9. 9
    Hannah R Briemberg, Anthony A Amato, Neuromuscular complications of cancer, Neurologic Clinics, 2003, 21, 1, 141

    CrossRef

  10. 10
    Kanokwan Boonyapisit, Henry J Kaminski, Robert L Ruff, Disorders of neuromuscular junction ion channels, The American Journal of Medicine, 1999, 106, 1, 97

    CrossRef

  11. 11
    DONALD B. SANDERS, 3,4-Diaminopyridine (DAP) in the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), Annals of the New York Academy of Sciences, 1998, 841, 1
    Direct Link:
  12. 12
    Dae S. Kim, Gwendolyn C. Claussen, Shin J. Oh, Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert–Eaton myasthenic syndrome, Muscle & Nerve, 1998, 21, 8
    Direct Link:
  13. 13
    Shin J. Oh, Dae S. Kim, Thomas C. Head, Gwen C. Claussen, Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome, Muscle & Nerve, 1997, 20, 9
    Direct Link:
  14. 14
    Kerry H. Levin, PARANEOPLASTIC NEUROMUSCULAR SYNDROMES, Neurologic Clinics, 1997, 15, 3, 597

    CrossRef

  15. 15
    J. Molgó, J. M. Guglielmi, 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome, Pflügers Archiv European Journal of Physiology, 1996, 431, S6, R295

    CrossRef

  16. 16
    Donald B. Sanders, Lambert-Eaton myasthenic syndrome: Clinical diagnosis, immune-mediated mechanisms, and update on therapies, Annals of Neurology, 1995, 37, S1
    Direct Link:
  17. 17
    Charlotte Vrinten, Stephanie S. Weinreich, Rob JPM Scholten, Jan JGM Verschuuren, 3,4-Diaminopyridine for myasthenia gravis, The Cochrane Library,
    Direct Link:
Get PDF (150K)